Go to Contents Go to Navigation

Celltrion to sell Truxima in 3 Latin American countries

Welfare/Medicine 09:15 February 04, 2019

SEOUL, Feb. 4 (Yonhap) -- Celltrion Healthcare Co., an affiliate of one of South Korea's leading biopharmaceuticals, said Monday that it has inked a series of deals in recent months to sell its biosimilar drug Truxima in three Central and South American countries.

Truxima -- based on Rituxan, originally developed by Swiss pharmaceutical giant Roche Holding AG -- will be sold in Ecuador, Guatemala and Costa Rica, the company said.

Celltrion Healthcare handles overseas business operations for Celltrion Inc.

Truxima is used in the treatment of a number of diseases in adult patients, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia, the company said.

The affiliate said it has recently won a contract through a bidding that was taken in Ecuador during the fourth quarter of last year.

Celltrion said it has so far won sales approval for Truxima from a total of seven Central and South American countries, and expects to earn additional approvals in Brazil, Chile and Peru this year.

Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire.

This undated photo provided by Celltrion Healthcare shows its biosimilar, Truxima. (Yonhap)


Send Feedback
How can we improve?
Thanks for your feedback!